Table 5.
Classes with medium percentage of rat carcinogens (mixed outcome class).
| Class | Total number of compounds | Compounds with tumors | Proposed final category | |
|---|---|---|---|---|
| 31 | AI, COX-2 inhibitors | 4 | 2 (50%) | TN |
| 32 | Antivirals | 10 | 4 (40%) | NT |
| 33 | CVS, ACE inhibitors | 9 | 5 (55%) | TN |
| 34 | CVS, adrenergic α1 antag. | 8 | 3 (38%) | TN |
| 35 | CVS, adrenergic α1 agonist | 2 | 1 (50%) | TN |
| 36 | CVS, adrenergic α2 agonist | 3 | 1 (33%) | TN |
| 37 | CVS, anticoagulant | 2 | 1 (50%) | TN |
| 38 | CVS, imidazoline agonists | 2 | 1 (50%) | TN |
| 39 | CVS, Na-channel blockers | 3 | 1 (33%) | TN |
| 40 | CVS, platelet aggreg. inhib. | 2 | 1 (50%) | NC |
| 41 | CVS, PDE3 inhibitors | 2 | 1 (50%) | TN |
| 42 | CNS, μ-opioid agonists | 3 | 1 (33%) | TN |
| 43 | CNS, 5HT1b/d agonists | 4 | 2 (50%) | TN |
| 44 | CNS, 5HT3 antagonists | 2 | 1 (50%) | TN |
| 45 | CNS, benzodiazepines | 5 | 2 (40%) | TN |
| 46 | CNS, antiepileptic, Na-channel blocker | 6 | 2 (33%) | TN |
| 47 | CNS, SNRIs | 4 | 2 (50%) | TN |
| 48 | RS, histamine H1 antag. | 7 | 2 (28%) | TN |
| 49 | GI, histamine H2 antag. | 4 | 2 (50%) | TN |
| 50 | MB, α-glycosidase inhibitors | 2 | 1 (50%) | TN |
| 51 | UB, anticholinergics | 5 | 3 (60%) | TN |
| 52 | IS, immunomodulators | 2 | 1 (50%) | NC |